Controversies in Surgical Management of Lymphedema

Summer E. Hanson, MD, PhD
Edward I. Chang, MD
Mark V. Schaverien, MD, MBChB, Med, MSc
Carrie Chu, MD
Jesse C. Selber, MD, MPH
Matthew M. Hanasono, MD

INTRODUCTION

The pathophysiology of lymphedema is heterogenous. Primary lymphedema may develop as a result of abnormal lymph flow due to aplastic, hypoplastic, or hyperplastic lymphatic channels and/or lymphatic valvular dysfunction. More commonly, secondary lymphedema manifests as a sequela of injury to the lymphatic system by way of lymphadenectomy, radiation, or trauma, any of which may result in impedence of the lymphatic system. Currently, there is no curative treatment for lymphedema. Conservative management includes life-long compression garments, complex decongestive therapy, and often activity modification. Advances in microsurgical technique have led to lymphaticovenular anastomosis (LVA), also known as lymphovenous bypass (LVB), and vascularized lymph node transfer (VLNT) as possible treatment options to restore physiologic lymphatic drainage. Although these techniques have effect through different mechanisms, the primary objective is to restore alternative means of lymph drainage. With LVA, the fluid is re-directed to the venous system. Alternatively, VLNT replaces the damaged or excised lymph nodes, and is hypothesized to work by absorbing lymphatic fluid or stimulating lymphangiogenesis with new lymphatic channel formation.1-3 While efficacy of both techniques has been demonstrated in numerous studies, there are several questions that remain. Here, the authors discuss the most pertinent controversies in our practice as well as the current state of surgical management of lymphedema.4-6

Summary: Surgical treatment of lymphedema has expanded in recent years. Lymphovenous bypass and vascularized lymph node transfer are both modern techniques to address the physiologic dysfunction associated with secondary lymphedema. While efficacy of both techniques has been demonstrated in numerous studies, there are several questions that remain. Here, the authors discuss the most pertinent controversies in our practice as well as the current state of surgical management of lymphedema. (Plast Reconstr Surg Glob Open 2020;8:e2671; doi: 10.1097/GOX.0000000000002671; Published online 25 March 2020.)

LVAs and the Number of Optimal Anastomoses

The concept of surgical connection of an obstructed lymphatic channel with a vein to alleviate the flow blockage first emerged in the 1960s.4,5 A mechanical bypass of the diseased segment of the lymphatic system diverts the flow of the obstructed, high pressure lymph channel contents into the lower pressure, patent venous system proximal to the site of lymphatic blockage.6 This physiologic solution received renewed attention in 2000 after Koshima et al7 pioneered supermicrosurgery techniques for Anastomosing vessels <0.8 mm in diameter. Since then, with vast improvements in technical experience, magnification technology, and precision instruments, interest in LVA continues to grow as a treatment strategy for lymphedema.8-12

One of several points of debate surrounding LVA is the ideal number of anastomoses to be performed to achieve maximal effectiveness. In their initial published experience, Koshima’s group described an average of 4 anastomoses per upper extremity, with as many as 10 LVAs when anatomy permitted.13,14 They believed that the number of anastomoses correlates positively with greater lymphovenous shunting and better outcomes.15 This rationale aligns with the experiences of others from the 1980’s.9-11 Huang et al16 performed an average of 4.5 anastomoses in 87 patients with lower extremity lymphedema, and observed that the patients who experienced the greatest amount of circumferential reduction underwent the highest mean number of LVAs [(>5 cm, 5.4 LVAs), (3–5 cm, 3.8 LVAs), (1–3 cm, 3.4 LVAs)]. Thus, the group advocated maximizing the number of LVAs. Mihara et al17 similarly reported a positive correlation between volume reduction and number of LVAs. However, the greater number of LVAs feasible in patients with early stage lymphedema may confound the observed positive association between anastomotic number and postoperative improvement.14,15,17 In the authors’ experience, patients presenting for surgical...
treatment of lymphedema rarely have >3 potential targets amenable to LVA.

In practice, Koshima et al 7 did not observe proportionate improvement in outcome with increasing numbers of LVAs performed per patient. Their technique evolved over the next several years into a minimally invasive approach under local anesthesia, with as few as 1–2 LVA completed in <2 hours. Among 52 patients with Campisi stage III and IV lymphedema of the lower extremities in their 2004 series, an average of 2.1 (±1.2) LVAs were performed with mean follow-up of 14.5 months, during which continued compression therapy was maintained. 10 The authors observed a 41.8% (±31.2%) reduction in limb circumference, with an 82% effectiveness rate as defined by any circumference reduction. 37 The authors’ rationale for the maintained efficacy despite reduction in number of LVAs is that the benefits of LVA extend beyond the mechanics of lymph diversion. They theorized that the LVA interrupts the vicious cycle of lymphatic hypertension, smooth muscle cell degeneration within lymphatic channels, fibrosis, exacerbated lymphatic channel dysfunction, and one well-executed LVA may suffice to halt the entire process. 14 The authors’ experience reinforces these findings and have found excellent improvement in patients’ lymphedema with as few as 1 LVA in an affected extremity.

In the absence of concrete evidence to support a critical threshold number of sufficient LVAs, heterogeneity in the approach to this matter persists. Potential confounding factors include lymphedema stage, upper versus lower extremity site, primary versus secondary etiology, surgeon experience and skill, vessel diameter, and anatomic configurations beyond end-to-end, including end-to-side, side-to-end, side-to-side, and multi-luminal “octopus” anastomoses. 10–22 While multisite single LVAs are common, 13,25 multiple LVAs may also be undertaken via a single exploratory incision. 16 Table 1 summarizes the number of LVAs performed per extremity in the largest published series dedicated to LVAs with consideration of some of the aforementioned variables, and describes outcomes using the reported subjective and/or objective measurement tools. In most studies, at least 3 LVAs per patient were performed.

Regardless of these unresolved controversies, there is consensus that the intrinsic contractility of the smooth muscle cells that comprise lymphatic channels is critical to the normal lymph flow. 29 Loss of this active pump mechanism observed in advanced, fibrotic stages of lymphedema is typically irreversible. Thus, it is intuitive that selection of functional lymphatic channels for LVA is paramount to the success of this procedure, and may explain the relatively diminished response observed in patients with primary lymphedema and those with greatest disease severity. 34,35 Garza and Chang 34 favor the use of intra-dermal injection of indocyanine green for lymphography-guided visualization of the functional lymphatic channels that are linear in appearance. This strategy was associated with greater numbers of LVA performed when compared with previous attempts without the technology. 31 Hara et al 32 have also advocated the selection of linear, splash, and stardust lymphography patterns representing normal, ectatic, and contraction vessels rather than use of sclerotic, nonfunctional channels for LVA.

LVB Compared with VLNT

While both LVA and VLNT have proven to be effective in improving patients’ lymphedema, considerable debate exists as to which technique is able to provide superior and more durable results. Historically, the authors’ approach was dictated based on indocyanine green (ICG) lymphangiography. In general, our algorithm stratified patients who had patent lymphatic channels demonstrated on ICG imaging (stage 1 and 2) as candidates for LVA, while those with more severe disease (stage 3 and 4) underwent VLNT. Unfortunately, a direct comparison of outcomes between LVA and VLNT would include a selection bias as most patients undergoing a VLNT were more advanced stage and did not have lymphatic channels to undergo a bypass operation.

In a study comparing 4 limbs treated with LVA and 15 limbs treated with VLNT for primary lymphedema, Cheng et al 33 found that both the LVA and VLNT were effective in improving lymphedema but a the VLNT group experienced a greater volume reduction (mean limb circumference reduction of 3.7 ± 2.9 cm and 1.9 ± 2.9 cm for VLNT and LVA, respectively; P = 0.2) and significantly more improvement in the Lymphedema Quality-of-Life score (from mean of 3.9 to mean of 6.4 and from mean of 3.0 to mean of 5.0 for VLNT and LVA, respectively; P < 0.05). However, the length of follow-up also needs to be taken into account in any study comparing the 2 modalities due to concern regarding the long-term patency of LVA. For example, in a study involving 12 patients with lymphedema treated with LVA, only 15 of 23 (56.5%) anastomoses were found to be patent after 12 months. 34 Despite the risks of thrombosis of the LVA, large cohort studies have demonstrated excellent success with both approaches, but well controlled data comparing LVA to VLNT is currently lacking. 35,36

Prophylactic Lymphedema Surgery

The significant impact that lymphedema has on quality of life after breast cancer treatment 7,28 has led to the exploration of preventative measures, particularly, prophylactic lymphedema surgery. Microsurgical LVA on the ipsilateral limb of patients undergoing radical mastectomy was first described nearly 3 decades ago. 3 More recently, several small studies and case reports have demonstrated variable results in preventing the development of secondary lymphedema following oncologic treatment. Lymphatic microsurgical preventive healing approach (LYMPHA) 40,41 is a technique that utilizes reverse mapping to identify and preserve upper arm lymphatics during axillary lymph node dissection. In addition, LVA to an axillary venous branch is performed at the time of oncologic surgery. Traditionally, these anastomoses were performed end to end or end to side; however, a more proximal location near the lymph node dissection is often associated with a larger size mismatch between the venous branches and primary lymphatics. To overcome this, several lymphatics can be sutured to the vein lumen using a U-shaped
| Study                        | Patients | Extremities | Disease Site | Stage | Primary versus Secondary | Lymphedema Duration (mean) | No. LVA | Mean Follow-up | Outcome Assessment Tool | Objective Result | Objective % Cases Improved | Subjective (%) |
|-----------------------------|----------|-------------|--------------|-------|--------------------------|---------------------------|---------|----------------|--------------------------|-----------------|--------------------------|----------------|
| Akita et al 2017            | NR       | Lower       | Stardust     | Secondary | 12 months               | 4.4                        | 12.1 months | LEL index      | 4% decline               | NR              | 58.6                    |
| Aljindan et al 2019         | 58       | Upper and lower | Cheng grade I–II | Primary and secondary | 43 months (median) | 1 | 16.5 months | Circumference measurement | 2.2%–3.2% decline | 100%                    |
| Chang et al 2013            | 89       | Upper       | MDA lympho Stage I–IV | Secondary | 42 months | NR | 30.4 months | Volumetry | 42% decline volume differential | NR | 96                     |
| Chang et al 2013            | 7        | Lower       | MDA lympho Stage I–IV | Secondary | 79 months | NR | 18.2 months | Volumetry | 6%–33% decline volume differential | NR | 57                     |
| Gennaro et al 2016          | 69       | Upper and lower | ISL II–IV | Primary and secondary | 69.6 months | 5.3 | “at least” 12 months | Circumference measurement | 50% decline volume differential | 100% had improvement | 81       |
| Hara et al 2018             | 109      | Upper and lower | ISL I–III Lympho I–V | Primary and secondary | 89.2 months | 3.3 | 9.1 months | Circumference measurement | 0.34%–1.83% decline | 100% had improvement | NR      |
| Huang et al 1985 III        | 91       | Lower       | ISL I–III Lympho I–V | Secondary | 135.6 months | 4.5 | 24 months | Circumference measurement | 59.2% decline volume differential | 100% had improvement | NR      |
| Koshima et al 2000          | 12       | Upper       | 11 “severe” | Secondary | 42 months | 4.1 | 26.4 months | Circumference measurement | 47.5% decline volume differential | 92% had improvement | NR      |
| Koshima et al 2003          | 13       | Lower       | NR           | Primary and secondary | 80.4 months | NR | 39.6 months | Circumference measurement | 55.6% decline volume differential | 100% had improvement | NR      |
| Koshima et al 2004          | 52       | Lower       | Campisi Stage III, IV | Secondary (primary NR) | 63.6 months | 2.1 | 14.5 months | Circumference measurement | 41.8% decline volume differential | 82.5% had improvement | NR      |
| Mihara et al 2014           | 95       | Upper and lower | ISL 0–III | Primary and secondary | NR | 3 or more | 27.3 months | No. cellulitis episodes | 1.46 episodes/year to 0.18 episodes/year | NR | NR      |
| Mihara et al 2016           | 84       | Lower       | ISL I–III Lympho I–V | Primary and secondary | NR | NR* | 18.3 months | Lymphoscintigraphy, circumference measurement | 58.9%–80% decline volume differential depending on stage | 47.7% had improvement | 61.5 |
| Seki et al 2015             | 30       | Lower       | LDB stage I–IV | Secondary | 41–63 months | 2 | 12 months | LEL, lymphoscintigraphy | 0.03–24.4 reduction LEL | 77% had improvement | NR      |
| Yamamoto et al 2014         | 48       | Lower       | ISL I–III | Primary and secondary | 66 months (median) | 1.6–1.8 | 6 months | LEL | 10.9–16.5 LEL | NR | NR      |

* Not reported; however, increased numbers of

ISL indicates International Society of Lymphology; LDB, lymphatic dermal back flow; LEL, lower extremity lymphedema index, combination of circumference measurement and body mass index; NR, not reported.
stitch. For most microsurgeons performing high volume lymphedema surgery, this approach is generally not recommended and an end-to-side anastomosis or perhaps a double barrel approach is more likely to have long-term patency and efficacy.

LYMPHA was attempted in 37 patients requiring axillary lymph node dissection and completed successfully in 27 with 6 months follow-up. Rates of upper extremity lymphedema were significantly lower in those with LYMPHA compared with those in whom the procedure could not be completed (12.5% versus 50%). Although there were no LYMPHA-related complications in their study, the procedure could not be completed in nearly a third of patients secondary to lack of suitable vessels for anastomosis. In their meta-analysis, Jørgensen et al reported a pooled lymphedema rate significantly less than that reported in the literature for patients treated with prophylactic LVA based on location of the lymphadenectomy: 5% for axillary, 12% for ilio-inguinal, 7% for para-aortic, and 0% for iliocalyx lymph node dissection. In quantitative analysis of 4 studies which included control groups, patients treated with prophylactic LVA had a relative risk of 0.33 (0.19, 0.56) for developing lymphedema compared with those not treated with LVA ($P < 0.0001$). Although the clinical results of prophylactic LVA are encouraging, like much of the field, well-designed, prospective studies with clearly defined outcome measures and adequate follow-up are still needed.

Lymph Node Flap Placement

While VLNT has become accepted as an efficacious treatment for advanced lymphedema, the optimal recipient site location for the lymph node flap remains a subject of controversy. Proponents of VLNT to a proximal location on the affected limb cite the opportunity for radical release of scar resulting from prior regional lymphadenectomy and radiation. In the setting of postmastectomy breast reconstruction, this is most commonly performed by transferring a deep inferior epigastric artery perforator flap with a chimeric groin vascularized lymph node flap placed in the axilla. Surgeons that support distal extremity VLNT placement cite the ability for the fluid to be absorbed from the most gravity-dependent position of the limb.

Clinical and experimental studies regarding the mechanisms of action of VLNT seem to suggest that either proximal and distal flap placement should help to reduce lymphedema. These include lymphangiogenesis and the “bridging” mechanism, whereby new afferent and efferent lymphatic collateral pathways connect the transplanted LNs with lymphatic vessels in the recipient site to restore outflow and the “pumping” mechanism whereby new lymphaticovenous drainage is established within the transplanted LNs, driven by perfusion gradients between the arterial inflow and venous outflow. Clinical studies also support favorable limb volume reduction outcomes for both proximal and distal VLNT in both the upper and lower extremities, although a randomized, prospective study comparing the 2 techniques has not been published. Under certain circumstances, dual-level transfer affords an opportunity to enhance the lymphatic drainage throughout the affected limb.

Donor Site Lymphedema

In counseling patients regarding VLNT for the treatment of lymphedema, the question of what the risk of causing lymphedema in the region drained by the transferred lymph nodes frequently arises. A systematic review by Demiri et al sought to answer this question. Looking only at VLNT for breast cancer-related lymphedema, the authors identified 3 cases of donor site lymphedema out of 189 patients (1.6%) collected from 11 studies that met their inclusion criteria. In a separate review of VLNT outcomes, encompassing 24 studies and 271 lymph node transfers, Scaglioni et al identified only the same 3 cases (1.1%) of iatrogenic lymphedema affecting the donor limb. An additional report by Lee et al describes a fourth case of donor limb lymphedema not included in either review.

Specifically, Vignes et al reported 2 cases of iatrogenic donor site lymphedema following groin lymph node transfer. These were made based on clinical diagnosis in which the donor limb was documented to have an increase of $>2$ cm in limb circumference compared with the contralateral limb. Pons et al reported 1 case of lower limb swelling after groin lymph node flap harvest in a series of 42 patients. The donor lower limb was found to have an increase in thigh circumference of 2 cm at 24 months follow-up and lymphoscintigraphy of the affected limb demonstrated delayed drainage, although dermal backflow pattern was not found. Although not included in either review, there is 1 case of upper extremity lymphedema that resulted following harvest of a supraclavicular lymph node flap confirmed with compromised drainage on lymphoscintigraphy and an increase of over 1 L in the ipsilateral arm.

Three of the 4 reported cases of iatrogenic lymphedema following VLNT come following groin lymph node harvest. It is not known whether groin lymph node harvest is inherently riskier than harvest from other potential donor sites (eg, supraclavicular, lateral thoracic, and intra-abdominal), or that more cases of donor site lymphedema have been reported following groin node harvest because it is a more common procedure than VLNT from other sites. One difficulty with estimating the risk of iatrogenic lymphedema following groin node transfer is that flap harvest techniques vary from surgeon to surgeon. For example, groin lymph node flaps have been described based on the superficial circumflex iliac artery (SCIA), superficial epigastric artery (SIEA), and the deep inferior epigastric artery. With regards to the reported cases of iatrogenic lymphedema following groin node transfer, Vignes et al described harvesting an “abundant amount of tissue” and Pons et al described harvesting “at least 3 lymph nodes” in the cases that resulted in donor limb lymphedema, leading Demiri et al to recommend limiting the number of lymph nodes harvested.

It may be that clinically symptomatic iatrogenic donor limb lymphedema is rare, but lymphatic function is still compromised. A few studies have looked at the lymphatic
Hanson et al. • Controversies in Lymphedema

function in the donor limb following groin VLNT. Viitanen et al. performed postoperative lymphoscintigraphy in 10 patients who underwent a SCIA-, or SCIA and SIEA-based groin lymph node flap transfer for BRCL. Minor changes in lymphatic flow were noted in 6 patients and the transport index (a sensitive and specific scoring system derived from lymphoscintigraphy findings) was abnormal in 2 patients. However, none of the patients complained of lymphedema symptoms in the donor limb nor was there a statistically significant difference in thigh circumference between the donor and non-donor limbs. In a follow-up study, the same group showed a smaller difference in limb volume between the donor limb and non-operated limb after modifying their groin lymph node flap harvest technique to only include the SCIA, no tissue medial to the femoral artery and inferior to the point where the tomic evidence suggests avoiding dissection medial to limb. For groin lymph node harvest, imaging and ana-

sentinel or major draining lymph nodes of the donor

rogenic lymphedema following VLNT include only har -

Recommendations for minimizing the chances of iat-

occurrence, although it may also be under-reported.

Based on the evidence available, it seems that symp-
tomatic iatrogenic donor site lymphedema is a rare occurrence, although it may also be under-reported. Recommendations for minimizing the chances of iatrogenic lymphedema following VLNT include only harvesting a small number of lymph nodes and sparing the sentinel or major draining lymph nodes of the donor limb. For groin lymph node harvest, imaging and ana-
tomic evidence suggests avoiding dissection medial to the femoral artery and inferior to the point where the superficial circumflex iliac vein joins the greater saphe-
nous vein. Reverse lymphatic mapping techniques may help to reduce iatrogenic lymphedema by identifying donor limb lymphatic tissues that should be preserved. As described by Dayan et al. radioative isotope (eg, tech-

netium) is injected into the lower limb to map the draining lymphatic tissues that should be left undisturbed while ICG dye is injected in the upper abdomen/lateral groin to identify lymphatic tissues to be included with the groin lymph node flap. Others have described utilizing magnetic resonance angiography or SPECT-CT lymphoscintigraphy preoperatively to guide selective lymph node harvest and spare the most functional lymph nodes for the donor limb. The authors recommend performing preoperative lymphoscintigraphy on all patients who are planning to have a VLNT using the inguinal, lateral thoracic, or supra-

clavicular donor sites. Donor site lymphedema following harvest of the omentum or gastroepiploic nodes, jejunal mesenteric nodes, or submental lymph nodes has never been reported, but in the authors’ opinion, there is no indication for obtaining preoperative imaging with the latter donor sites.

CONCLUSIONS

With many significant advances in super microsurgery, a surgical approach to lymphedema is increasingly common, though many controversies remain. Each of these—from optimal technique to prophylactic surgery to donor-site lymphedema—represents an area of ongoing investigation. The authors find that in our high-volume center, with both multi-disciplinary evaluation and multi-

modal approach, surgical treatment of lymphedema is patient-specific, safe, and efficacious.

Matthew M. Hanasono, MD, FACS
Department of Plastic Surgery, Unit 1488
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
E-mail: mhanasono@mdanderson.org

REFERENCES

1. Aschen SZ, Farias-Eisner G, Cuzzone DA, et al. Lymph node transplantation results in spontaneous lymphatic reconnec-
tion and restoration of lymphatic flow. Plast Reconstr Surg. 2014;133:301–310.

2. Ito R, Zelken J, Yang CY, et al. Proposed pathway and mecha-
nism ofvascularized lymph node flaps. Gynecol Oncol. 2016;141:182–188.

3. Yan A, Avraham T, Zampell JC, et al. Mechanisms of lymphatic regeneration after tissue transfer. Plast Reconstr Surg. 2011;128:1720–1726.

4. Jacobson JH II, Suarez EL. Microvascular surgery. Dis Chest. 1962;41:220–224.

5. Nielubowicz J, Olszewski W. Surgical lymphaticovenous shunts in patients with secondary lymphoedema. Br J Surg. 1968;55:440–442.

6. O’Brien BM. Microlymphaticovenous surgery for obstructive lymphoedema. Aust N Z J Surg. 1977;47:284–291.

7. Koshima I, Inagawa K, Urushibara K, et al. Supermicrosurgical lymphaticovenular anastomosis for the treatment of lymphedema in the upper extremities. J Reconstr Microsurg. 2000;16:437–442.

8. O’Brien BM, Mellow CG, Khazanchi RK, et al. Long-term results after microlymphaticovenous anastomoses for the treatment of obstructive lymphedema. Plast Reconstr Surg. 1990;85:562–572.

9. Huang GK, Hu RQ, Liu ZZ, et al. Microlymphaticovenous anas-
tomosis in the treatment of lower limb obstructive lymphedema: analysis of 91 cases. Plast Reconstr Surg. 1985;76:671–685.

10. Matsubara S, Sakuda H, Nakaena M, et al. Long-term results of microscopic lymphatic vessel-isolated vein anastomosis for secondary lymphedema of the lower extremities. Surg Today. 2006;36:859–864.

11. Chang DW, Suami H, Skoracki R. A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema. Plast Reconstr Surg. 2013;132:1305–1314.
12. Mihara M, Hara H, Tange S, et al. Multisite lymphaticovenular bypass using supermicrosurgery technique for lymphedema management in lower lymphedema cases. Plast Reconstr Surg. 2016;138:262–272.
13. Koshima I, Inagawa K, Etoh K, et al. [Supramicrosurgical lymphaticovenous anastomosis for the treatment of lymphedema in the extremities]. Nikko Geka Gakkai Zasshi. 1999;100:551–556.
14. Giovizczi P, Fisher J, Hollier LH, et al. Microsurgical lymphovenous anastomosis for treatment of lymphedema: a critical review. J Vasc Surg. 1988;7:647–652.
15. Mihara M, Hara H, Kawakami Y, et al. Multi-site lymphatic venous anastomosis using echography to detect suitable subcutaneous vein in severe lymphedema patients. J Plast Reconstr Aesthet Surg. 2018;71:1–7.
16. Campisi C, Boccardo F, Zilli A, et al. Long-term results after lymphaticovenous anastomoses for the treatment of obstructive lymphedema. Microsurgery. 2001;21:135–139.
17. Koshima I, Nanba Y, Tsutsui T, et al. Minimal invasive lymphaticovenous anastomosis under local anesthesia for leg lymphedema: is it effective for stage III and IV? Ann Plast Surg. 2004;53:261–266.
18. Nagase T, Gonda K, Inoue K, et al. Treatment of lymphedema with lymphaticovenous anastomoses. Int J Clin Onkol. 2005;10:304–310.
19. Narushima M, Mihara M, Yamamoto Y, et al. The intravascular stenting method for treatment of extremity lymphedema with multiconfiguration lymphaticovenous anastomoses. Plast Reconstr Surg. 2010;125:935–943.
20. Yamamoto T, Kikuchi K, Yoshimatsu H, et al. Ladder-shaped lymphaticovenular anastomosis using multiple side-to-side lymphatic anastomoses for a leg lymphedema patient. Microsurgery. 2014;34:404–408.
21. Ito R, Wu CT, Lin MC, et al. Successful treatment of early-stage lower extremity lymphedema with side-to-end lymphovenous anastomosis with indocyanine green lymphography assisted. Microsurgery. 2014;36:310–315.
22. Chen WF, Yamamoto T, Fisher M, et al. The “octopus” lymphaticovenular anastomosis: evolving beyond the standard supermicrosurgical technique. J Reconstr Microsurg. 2015;31:450–457.
23. Akita S, Tokumoto H, Yamaji Y, et al. Contribution of simultaneous breast reconstruction by deep inferior epigastric artery perforator flap to the efficacy of vascularized lymph node transfer in patients with breast cancer-related lymphedema. J Reconstr Microsurg. 2017;33:571–578.
24. Alljindan FK, Lin CY, Cheng MH. Comparison of outcomes between side-to-end and end-to-end lymphovenous anastomoses for early-grade extremity lymphedema. Plast Reconstr Surg. 2019;144:486–496.
25. Gennaro P, Gabriele G, Mihara M, et al. Supramicrosurgical lymphatic-venular anastomosis (LVA) in treating lymphedema: 36-months preliminary report. Eur Rev Med Pharmacol Sci. 2016;20:4642–4653.
26. Hara H, Mihara M. Multi-area lymphaticovenous anastomosis with multi-lymphosome injection in indocyanine green lymphography: a prospective study. Microsurgery. 2019;39:167–173.
27. Mihara M, Hara H, Furniss D, et al. Lymphaticovenular anastomosis to prevent cellulitis associated with lymphedema. Br J Surg. 2014;101:1391–1396.
28. Seki Y, Yamamoto T, Yoshimatsu H, et al. The superior edge of knee incision method in lymphaticovenular anastomosis for lower extremity lymphedema. Plast Reconstr Surg. 2015;136:665e–675e.
29. von der Weid PY, Zawieja DC. Lymphatic smooth muscle: the motor unit of lymph drainage. Int J Biochem Cell Biol. 2004;36:1147–1153.
30. Hara H, Mihara M, Ohitsu H, et al. Indication of lymphaticovenous anastomosis for lower limb primary lymphedema. Plast Reconstr Surg. 2015;136:883–893.
31. Garza RM, Chang DW. Lymphovenous bypass for the treatment of lymphedema. J Surg Oncol. 2018;118:745–749.
32. Hara H, Mihara M, Seki Y, et al. Comparison of indocyanine green lymphographic findings with the conditions of collecting lymphatic vessels of limbs in patients with lymphedema. Plast Reconstr Surg. 2013;132:1612–1618.
33. Cheng MH, Loh CY, Lin CY. Outcomes of vascularized lymph node transfer and lymphovenous anastomosis for treatment of primary lymphedema. Plast Reconstr Surg Glob Open. 2018;6:e2056.
34. Winters H, Tielens HJP, Verhulst AC, et al. The long-term patency of lymphaticovenular anastomosis in breast cancer-related lymphedema. Ann Plast Surg. 2019;82:196–200.
35. Scaglioni MF, Fontine DB, Arvanitakis M, et al. Systematic review of lymphovenous anastomosis (LVA) for the treatment of lymphedema. Microsurgery. 2017;37:947–953.
36. Scaglioni MF, Arvanitakis M, Chen YC, et al. Comprehensive review of vascularized lymph node transfers for lymphedema: outcomes and complications. Microsurgery. 2018;38:222–229.
37. Moffatt CJ, Franks PJ, Doherty DC, et al. Lymphoedema: an underestimated health problem. QJM. 2003;96:731–738.
38. Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147–154.
39. Pronin VI, Adamian AA, Zolotarevski V, et al. Creation of lymphovenous anastomoses in the early period after radical mastectomy. Sov Med. 1989;77–79.
40. Boccardo FM, Casabona F, Friedman D, et al. Surgical prevention of arm lymphedema after breast cancer treatment. Ann Surg Oncol. 2011;18:2500–2505.
41. Boccardo F, Casabona F, De Cian F, et al. Lymphatic microsurgical preventing healing approach (LYMPHA) for primary surgical prevention of breast cancer-related lymphedema: over 4 years follow-up. Microsurgery. 2014;34:421–424.
42. Feldman S, Bansil H, Ascherman J, et al. Single institution experience with lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema. Ann Surg Oncol. 2015;22:3296–3301.
43. Jørgensen MG, Toysenki NM, Sørensen JA. The effect of prophylactic lymphovenous anastomosis and shunts for preventing cancer-related lymphedema: a systematic review and meta-analysis. Microsurgery. 2018;38:576–585.
44. Becker C, Assouad J, Riquet M, et al. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg. 2006;243:313–315.
45. Saaristo AM, Niemi TS, Viitanen TP, et al. Microvascular breast reconstruction and lymph node transfer for postmastectomy lymphedema patients. Ann Surg Oncol. 2012;25:488–473.
46. Nguyen AT, Chang EI, Suami H, et al. An algorithmic approach to simultaneous vascularized lymph node transfer with microvascular breast reconstruction. Ann Surg Oncol. 2012;22:2919–2924.
47. Cheng MH, Chen SC, Henry SL, et al. Vascularized groin lymph node flap transfer for postmastectomy upper limb lymphedema: flap anatomy, recipient sites, and outcomes. Plast Reconstr Surg. 2013;131:1296–1298.
48. Cheng MH, Huang JJ, Nguyen DH, et al. A novel approach to the treatment of lower extremity lymphedema by transferring a vascularized submental lymph node flap to the ankle. Gynecol Oncol. 2012;135:93–98.
49. Cheng MH, Chen SC, Henry SL, et al. Reply: vascularized groin lymph node flap transfer for postmastectomy upper limb lymphedema: the flap anatomy, recipient sites, and outcomes. Plast Reconstr Surg. 2014;133:428e–429e.
50. Patel KM, Lin CY, Cheng MH. A prospective evaluation of lymphedema-specific quality-of-life outcomes following vascularized lymph node transfer. *Ann Surg Oncol.* 2015;22:2424–2430.
51. Smith ML, Molina BJ, Dayan E, et al. Heterotopic vascularized lymph node transfer to the medial calf without a skin paddle for restoration of lymphatic function: proof of concept. *J Surg Oncol.* 2017;115:90–95.
52. Shesol BF, Nakashima R, Alavi A, et al. Successful lymph node transplantation in rats, with restoration of lymphatic function. *Plast Reconstr Surg.* 1979;63:817–823.
53. Viitanen TP, Visuri MT, Hartiala P, et al. Lymphatic vessel function and lymphatic growth factor secretion after microvascular lymph node transfer in lymphedema patients. *Plast Reconstr Surg Glob Open.* 2013;1:1–9.
54. Huang JJ, Gardenier JC, Hespe GE, et al. Lymph node transplantation decreases swelling and restores immune responses in a transgenic model of lymphedema. *PLoS One.* 2016;11:e0168259.
55. Suami H, Scaglioni MF, Dixon KA, et al. Interaction between vascularized lymph node transfer and recipient lymphatics after lymph node dissection-a pilot study in a canine model. *J Surg Res.* 2016;204:418–427.
56. Chen HC, O’Brien BM, Rogers IW, et al. Lymph node transfer for the treatment of obstructive lymphoedema in the canine model. *Br J Plast Surg.* 1990;43:578–586.
57. Patel KM, Lin CY, Cheng MH. From theory to evidence: long-term evaluation of the mechanism of action and flap integration of distal vascularized lymph node transfers. *J Reconstr Microsurg.* 2015;31:26–30.
58. Gratzon A, Schultz J, Secret K, et al. Clinical and psychosocial outcomes of vascularized lymph node transfer for the treatment of upper extremity lymphedema after breast cancer therapy. *Ann Surg Oncol.* 2017;24:1475–1481.
59. Dionysiou D, Demiri E, Tsimponis A, et al. A randomized control study of treating secondary stage II breast cancer-related lymphoedema with free lymph node transfer. *Breast Cancer Res Treat.* 2016;156:73–79.
60. Liu HL, Pang SY, Lee CC, et al. Orthotopic transfer of vascularized groin lymph node flap in the treatment of breast cancer-related lymphoedema: clinical results, lymphoscintigraphy findings, and proposed mechanism. *J Plast Reconstr Aesthet Surg.* 2018;71:1033–1040.
61. Lin CH, Ali R, Chen SC, et al. Vascularized groin lymph node transfer using the wrist as a recipient site for management of postmastectomy upper extremity lymphedema. *Plast Reconstr Surg.* 2009;123:1265–1275.
62. Gustafsson J, Chu SY, Chan WH, et al. Correlation between quantity of transferred lymph nodes and outcome in vascularized submental lymph node flap transfer for lower limb lymphedema. *Plast Reconstr Surg.* 2018;142:1056–1063.
63. Ciudad P, Manrique OJ, Dale S, et al. Double gastroepiploic vascularized lymph node transfer to middle and distal limb for the treatment of lymphedema. *Microsurgery.* 2017;37:771–779.
64. Kenworthy EO, Nelson JA, Verma R, et al. Double vascularized omentum lymphatic transplant (VOLT) for the treatment of lymphedema. *J Surg Oncol.* 2018;117:1413–1419.
65. Demiri E, Dionysiou D, Tsimponis A, et al. Donor-site lymphedema following lymph node transfer for breast cancer-related lymphoedema: a systematic review of the literature. *Lymphat Res Biol.* 2018;16:2–8.
66. Lee M, McClure E, Reinertsen E, et al. Lymphoedema of the upper extremity following supraclavicular lymph node harvest. *Plast Reconstr Surg.* 2015;135:1079e–1082e.
67. Vignes S, Blanchard M, Yannoutsos A, et al. Complications of autologous lymph-node transplantation for limb lymphoedema. *Eur J Vasc Endovasc Surg.* 2013;45:516–520.
68. Pons G, Masia J, Loschi P, et al. A case of donor-site lymphoedema after lymph node-superficial circumflex iliac artery perforator flap transfer. *J Plast Reconstr Aesthet Surg.* 2014;67:119–125.
69. Viitanen TP, Mäki MT, Seppänen MP, et al. Donor-site lymphatic function after microvascular lymph node transfer. *Plast Reconstr Surg.* 2012;130:1246–1253.
70. Salo E, Hartiala P, Viitanen T, et al. Risk of donor-site lymphatic vessel dysfunction after microvascular lymph node transfer. *J Plast Reconstr Aesthet Surg.* 2015;68:551–558.
71. Liu HL, Pang SY, Lee CC. Donor limb assessment after vascularized groin lymph node transfer for the treatment of breast cancer-related lymphoedema: clinical and lymphoscintigraphy findings. *J Plast Reconstr Aesthet Surg.* 2019;72:216–224.
72. Dayan JH, Dayan E, Smith ML. Reverse lymphatic mapping: a new technique for maximizing safety in vascularized lymph node transfer. *Plast Reconstr Surg.* 2015;135:277–285.